[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Investigation Report on China Simvastatin Market, 2010-2019

June 2015 | 40 pages | ID: ICF988D7754EN
China Research and Intelligence Co., Ltd.

US$ 2,000.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Description

Lyperlipidemia, a common disease in present society, has become one of the three health killers with an increasing incidence. Lyperlipidemia can lead to atherosclerosis, coronary heart disease, stroke, myocardial infarction, hemiplegia and so on. Besides, a high level of blood fat will induce such severe diseases as hypertension, hyperglycemia, fatty liver, pancreatitis and fundus hemorrhage which not only cause serious damage but also influence patients’ life quality.

With the sustained economic development and the improvements in diet, Chinese people’s blood fat level rises too. Many local epidemiological studies on blood fat have proved that a conservative estimate of the incidence of hyperlipemia is 7%-8% while the actual incidence might be above 10%. Over 100 million people in China have to receive cholesterol-lowering therapy, more so with the coming ageing society. As people increasingly pay attention to health, cholesterol-lowering drugs will become more and more promising. The annual market size of statin drug is estimated to surpass USD 20 billion around the world, growing at an annual rate of 20% .

Simvastatin, a new generation of HMG-COA reductase inhibitor produced by restructuring lovastatin, was introduced into China by MSD (China) in 1995. Domestic simvastatin was developed by Sichuan Industrial Institute of Antibiotics. Simvastatin develops fast after entering China, sales value being CNY 104 million in 2005 and CNY 197 million in 2010. However, later, its sales began to drop to CNY 156 million in 2014. Hangzhou MSD Pharmaceutical Co., Ltd, Merck Sharp & Dohme (UK), Guangzhou Nanxin Pharmaceutical Co., Ltd, Sichuan Hairong Pharmaceutical Co., Ltd and Shandong Lukang Pharmaceutical Co., Ltd occupy the majority of market, among which Hangzhou MSD Pharmaceutical Co., Ltd has the largest market share of 39% for sales value in 2014.

The sales value of simvastatin will stay at a certain level in a given period despite a downtrend in recent years.

Readers can get at least the following information from this report:
  • market size of simvastatin in China
  • price of simvastatin in China
  • market outlook of simvastatin in China
The author suggests the following groups of people purchase this report:
  • manufacturers of lipid-lowering drugs
  • investors/ research institutions interested in Chinese medicine market
  • any interest in the Chinese medicine market, please contact CRI for customized survey service
1 RELATED CONCEPTS OF SIMVASTATIN

1.1 Indication
1.2 Sales Status in Global Market

2 MARKET PROFILE OF SIMVASTATIN IN CHINA

2.1 Patent and Approval Status of Simvastatin in China
2.2 Major Manufacturers
2.3 Market Size

3 SURVEY ON SALES STATUS OF SIMVASTATIN IN CHINA, 2010-2014

3.1 Sales Value
  3.1.1 Overall Sales Value
  3.1.2 Sales Value by Regions
3.2 Sales Volume
  3.2.1 Overall Sales Volume
  3.2.2 Sales Volume by Regions

4 SURVEY ON MARKET SHARE OF MAJOR MANUFACTURERS OF SIMVASTATIN IN CHINA, 2010-2014

4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume

5 SURVEY ON DOSAGE FORMS OF SIMVASTATIN IN CHINA, 2010-2014

5.1 Share of Different Dosage Forms by Sales Value
5.2 Share of Different Dosage Forms by Sales Volume

6 REFERENCE PRICE OF SIMVASTATIN IN CHINESE HOSPITALS IN 2014

6.1 Hangzhou MSD Pharmaceutical Co., Ltd (Trade Name: Shujiangzhi)
6.2 Sichuan Hairong Pharmaceutical Co., Ltd (Trade Name: Xindasu)
6.3 Shandong Lukang Pharmaceutical Co., Ltd (Trade Name: Xinglu)
6.4 Guangzhou Nanxin Pharmaceutical Co., Ltd (Trade Name: Simcor)
6.5 Cinmed Pharmaceuticals CP (Trade Name: Jianzhiting)
6.6 Merck Sharp & Dohme (UK) (Trade Name: Zocor)

7 MAJOR MANUFACTURERS OF SIMVASTATIN IN CHINESE MARKET, 2010-2014

7.1 Cinmed Pharmaceuticals CP
7.2 Guangzhou Nanxin Pharmaceutical Co., Ltd
7.3 Shandong Lukang Pharmaceutical Co., Ltd
7.4 Sichuan Hairong Pharmaceutical Co., Ltd
7.5 Merck Sharp & Dohme

8 MARKET OUTLOOK OF SIMVASTATIN IN CHINA, 2015-2019

8.1 Forecast of Market Size
8.2 Forecast of Competitive Landscape

TABLE OF SELECTED CHARTS

Chart Patent Status of Simvastatin in China
Chart Approval Information of Simvastatin in China
Chart Sales Status of Simvastatin in China
Chart Sales Value of Simvastatin in China, 2010-2014
Chart Sales Value of Simvastatin in Some Regions in China, 2010-2014
Chart Sales Volume of Simvastatin in China, 2010-2014
Chart Sales Volume of Simvastatin in Some Regions in China, 2010-2014
Chart Market Share of TOP5 Manufacturers of Simvastatin for Sales Value in China, 2010-2014
Chart Sales Value and Market Share of Simvastatin Made by Hangzhou MSD in China, 2010-2014
Chart Sales Value and Market Share of Simvastatin Made by Merck Sharp & Dohme (UK) in China, 2010-2014
Chart Sales Value and Market Share of Simvastatin Made by Guangzhou Nanxin in China, 2010-2014
Chart Sales Value and Market Share of Simvastatin Made by Cinmed in China, 2010-2014
Chart Sales Value and Market Share of Simvastatin Made by Shandong Lukang Pharmaceutical in China, 2010-2014
Chart Sales Value and Market Share of Simvastatin Pills in China, 2010-2014
Chart Sales Value and Market Share of Simvastatin Tablets in China, 2010-2014
Chart Sales Value and Market Share of Simvastatin Capsules in China, 2010-2014
Chart Price of Simvastatin Made by Hangzhou MSD Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
Chart Price of Simvastatin Made by Sichuan Hairong Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
Chart Price of Simvastatin Made by Shandong Lukang Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
Chart Price of Simvastatin Made by Guangzhou Nanxin Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
Chart Price of Simvastatin Made by Cinmed Pharmaceuticals CP in Some Chinese Cities in 2014
Chart Price of Simvastatin Made by Merck Sharp & Dohme (UK) in Some Chinese Cities in 2014


More Publications